Section Arrow
Quote
TLX.NASDAQ
- Telix Pharmaceuticals Ltd.
Quotes are at least 15-min delayed:2026/04/10 20:14 EDT
Regular Hours
Last
 10.54
+0.74 (+7.55%)
Day High 
10.71 
Prev. Close
9.8 
1-M High
9.95 
Volume 
432.58K 
Bid
10.2
Ask
10.75
Day Low
10.1 
Open
10.275 
1-M Low
7.575 
Market Cap 
3.32B 
Currency 美元 
P/E 298.51 
%Yield -- 
10-SMA 9.34 
20-SMA 8.89 
50-SMA 7.84 
52-W High 20 
52-W Low 6.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.02/0.03
Enterprise Value
3.77B
Balance Sheet
Book Value Per Share
1.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
803.79M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.